Abstract

The objective of this study was to retrospectively evaluate preoperative imaging modalities for localization of parathyroid adenomas with a view to enable minimally invasive parathyroidectomy and in particular, to consider the contribution of 18F-fluorocholine-PET/CT. 104 patients with primary hyperparathyroidism, who underwent parathyroid surgery in a single centre during a 6-year period were included. Of these, 103 underwent ultrasound, 97 99mTc-Pertechnetate/SestaMIBI-SPECT, 20 MRI and 30 18F-fluorocholine-PET/CT. Based on surgical findings, sensitivities and specificities for correct lateralisation in orthotopic locations were: for ultrasound 0.75 (0.65–0.83) and 0.89 (0.81–0.94), for 99mTc-MIBI-SPECT 0.57 (0.46–0.67) and 0.97 (0.91–0.99), for MRI 0.60 (0.36–0.81) and 0.83 (0.59–0.96) and for 18F-fluorocholine-PET/CT 0.90 (0.73–0.98) and 0.90 (0.73–0.98). Correctly lateralized adenomas were significantly larger than those not found with ultrasound (p = 0.03) and SPECT (p = 0.002). Pre-operative PTH-levels were higher in single adenomas detected by scintigraphy than in those not (p = 0.02). 64 patients could be treated with a minimally invasive procedure. Cure after parathyroidectomy was obtained in 94% of patients. 18F-Fluorocholine-PET/CT could be shown to be a highly accurate modality to localize parathyroid adenomas preoperatively, obviating the need for total exploration in the majority of patients in whom ultrasound and scintigraphic results are discordant or both negative.

Details

Title
Retrospective real-life study on preoperative imaging for minimally invasive parathyroidectomy in primary hyperparathyroidism
Author
Bijnens, Jacqueline 1   VIAFID ORCID Logo  ; Van den Bruel, Annick 2   VIAFID ORCID Logo  ; Vander Poorten, Vincent 3   VIAFID ORCID Logo  ; Goethals, Ingeborg 4   VIAFID ORCID Logo  ; Van Schandevyl, Steven 4   VIAFID ORCID Logo  ; Dick, Catherine 1   VIAFID ORCID Logo  ; De Geeter, Frank 5   VIAFID ORCID Logo 

 AZ Sint-Jan, Otorhinolaryngology-Head and Neck Surgery, Bruges, Belgium (GRID:grid.420036.3) (ISNI:0000 0004 0626 3792) 
 AZ Sint-Jan, Internal Medicine, Endocrinology, Bruges, Belgium (GRID:grid.420036.3) (ISNI:0000 0004 0626 3792) 
 University Hospitals Leuven, Otorhinolaryngology-Head and Neck Surgery, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338); Leuven Cancer Institute, KU Leuven, Department of Oncology, Section Head and Neck Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884) 
 Ghent University Hospital, Nuclear Medicine, Ghent, Belgium (GRID:grid.410566.0) (ISNI:0000 0004 0626 3303) 
 AZ Sint-Jan, Nuclear Medicine, Bruges, Belgium (GRID:grid.420036.3) (ISNI:0000 0004 0626 3792) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2726144841
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.